Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 12/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165550 | 0.91 | TAS2R14 (0.57) | TAS2R14CXCR3PTGES | |
| SCHEMBL4956610 | 0.82 | PTPRB (0.47) | KDM4EALDH1A1MAPT | |
| SCHEMBL5166021 | 0.81 | PTPN1 (0.65) | TAS2R14KDM4EALDH1A1MAPT | |
| SCHEMBL5163635 | 0.78 | PTPN1 (0.53) | TAS2R14KDM4EALDH1A1POLBMAPT | |
| SCHEMBL13939149 | 0.76 | TAS2R14 (0.77) | TAS2R14POLBMAPTCXCR3PTGES | |
| SCHEMBL5188296 | 0.75 | PTPN1 (0.62) | — | |
| SCHEMBL5499145 | 0.74 | FAAH (0.40) | KDM4EALDH1A1MAPTTP53 | |
| SCHEMBL4899408 | 0.74 | HDAC1 (0.42) | ALDH1A1 | |
| SCHEMBL1169700 | 0.74 | TAS2R14 (0.75) | TAS2R14POLBMAPTCXCR3PTGES | |
| SCHEMBL4954893 | 0.74 | RAB9A (0.40) | KDM4EALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | TAS2R14 4230/4885KDM4E 345/4885ALDH1A1 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.